Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bayer
Biotech
Bayer moves allogeneic cell therapy into ph. 3 Parkinson's trial
BlueRock's cell therapy will be assessed in a double-blind phase 3 study for Parkinson's disease that is expected to start in the first half of 2025.
Gabrielle Masson
Jan 13, 2025 2:30am
Bayer’s hot flash drug hits goal in phase 3 breast cancer trial
Jan 9, 2025 7:40am
Sanofi scoops up China rights to Cytokinetics' heart disease med
Dec 20, 2024 11:07am
Bayer drops Huntington's gene therapy
Nov 12, 2024 10:09am
Biopharma layoff rate stabilizes in Q3: Fierce Biotech analysis
Oct 4, 2024 3:50pm
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Sep 10, 2024 7:57am
